The Center to Advance Palliative Care suggests steps cardiologists can take to ensure ongoing identification and management of remediable sources of suffering and distress in heart failure patients.

The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.

A large-scale study of people living with HIV has linked the immune deficiency to an increased risk of CVD, in particular heart failure and stroke.

Heart patients of a lower socioeconomic status are far more likely to participate in cardiac rehabilitation if they receive financial incentives to attend sessions, according to a study published in the July 1 edition of JACC: Heart Failure.

The FDA on June 26 granted Boehringer Ingelheim and Eli Lilly and Company’s drug empagliflozin Fast Track designation for the treatment of chronic heart failure, the companies announced.

One in five Americans are able to recognize the symptoms of heart failure, according to a new survey from Abbott—a troublesome finding considering the same research puts the average individual just four degrees of separation from HF.

Researchers at Imperial College London have developed a sew-on heart patch that leverages stem cells to support and repair heart muscle after a heart attack—something that could dramatically lower MI survivors’ risk of future heart failure.

Loneliness, above all else, was an independent predictor of whether patients stuck to their doctors’ guidelines.